Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Collaborations
Pharma company exercises rights to Centocor's CNTO 148
September 14th, 2005
Schering-Plough Corporation (SGP) announced that it has exercised its rights to develop and commercialize with Centocor Inc., CNTO 148. CNTO 148 is a fully human monoclonal antibody being developed as a therapy for the treatment of rheumatoid arthritis and other immune-mediated inflammatory diseases, as provided under a 1998 agreement between Schering-Plough and Centocor. As a result of the decision to exercise its rights to the compound, Schering-Plough expects to record an research and development (R&D) charge of approximately $125 million in the third quarter for R&D costs previously incurred by Centocor. Schering-Plough and Centocor will share...
Source: Vaccine Weekly (2005-09-14)
|
